RUCH Spółka z Ograniczoną Odpowiedzialnością (KRS 0000448917, NIP 7010370222) is a Polish company, headquartered in Warszawa, Mazowieckie voivodeship. RUCH operates in: Research and experimental development on social sciences and humanities (PKD 72.20.Z). Industry: Research and development. The company has been listed in the National Court Register since January 25, 2013. RUCH's most recently reported net revenue was 10.0 K PLN for 2024.
Negative equity
Negative equity in 1 of 7 available reporting years.
No arrears identified in the analyzed sources
No arrears or bankruptcy proceedings identified in the analyzed sources.
Business profile - RUCH
Identity
- Name
- RUCH Spółka z Ograniczoną Odpowiedzialnością
- Legal form
- SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
- Founded
- January 25, 2013
- Registry status as of
- November 21, 2025
- Latest entry
- September 2, 2025
- Founding act
- 24.01.2013
Articles of association history (1)
- January 24, 2013: 24.01.2013
Activities
Main activity
72.20.ZResearch and experimental development on social sciences and humanities
General codes (divisions and groups)
General codes indicate a PKD division or group without a specific subclass.
Address and contact
- Address
- UL. ELEKTORALNA, 13, 121, 00-137, WARSZAWA, POLSKA
- Voivodeship
- MAZOWIECKIE
- District
- WARSZAWA
- Not disclosed in the registry
- Website
- Not disclosed in the registry
- E-delivery address
- AE:PL-49656-27598-WCAIT-36
- Coordinates
- 52.2298, 21.0117approx.
Risk and payment profile - RUCH
Credibility rating
54.3 / 100
Average credibility
Insolvency risk
Very low
Elevated threat
Closure risk
4
/ 100
Risk comparison - scale 0 (safe) → 100 (critical)
Organizational stability signals
No instability signals - ownership, management, PKD codes and company name remain relatively stable.
Shareholder changes
0
0/13 yrs
Board changes
0
0/13 yrs
PKD changes
1
1/13 yrs
Name changes
0
0/13 yrs
Data from 13 years of registry activity.
Credibility history
Payment reliability score from 2018–2024
Current: D (54/100)
Trend: improving (+6.3 pts/year)
Słaba wiarygodność płatnicza – wskaźniki finansowe sugerują podwyższone ryzyko opóźnień lub niewykonania zobowiązań.
Trade credit limit history
Standard limit from 2018–2024
Current: 1.2 K PLN
Safe: 365.77 PLN
Difference between risk models
Closure - probability of ceasing operations (operational continuity). Insolvency - probability of formal bankruptcy / restructuring. The models use different data - results can diverge significantly when balance-sheet data is incomplete.
Operational status - RUCH
Founded
January 25, 2013
13 years in operation
Legal form
SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
Registry: RejP
Headquarters
WARSZAWA
MAZOWIECKIE
Primary PKD
72.20.Z
Research and experimental development on social sciences and humani…
Share capital
10.0 K PLN
99 shares total
Shareholders
1
shareholder
Board
1 person
Filed years
7 years
2018–2024 · profitable: 6/7
Registry entries
37
latest: September 2, 2025
Risk signals
Revenue
10.0 K PLN
2024
Net profit
515.99 PLN
2024
Assets
25.6 K PLN
2024
Equity
9.6 K PLN
2024
EBITDA
N/A
2024
no depreciation data
Valuation
4.8 K PLN
Low confidence
Low confidence
Market comparison RUCH
Comparison with PKD sector 72.20.Z
Market position (2024)
Sector median - total assets
Company - total assets
Public procurement
Trademarks
Reviews
Rate business credibility - RUCH.
Related articles
News
Bioceltix in the final EMA dialogue phase: BCX-CM-J could become Europe's first veterinary cell-therapy drug for dogs
Wrocław-based Bioceltix S.A. (KRS 0000744521) entered Q2 2026 in the final EMA dialogue phase regarding BCX-CM-J - Europe's first veterinary cell-therapy drug from mesenchymal stem cells for dogs with osteoarthritis. Responses to the final EMA questions are due in May 2026; the CVMP recommendation and marketing authorisation are possible in Q3/Q4 2026. Pre-commercial biotech: 2024 closed with a PLN 14.9 m loss on zero revenue; cash of PLN 33.6 m at year-end. Trigon DM maintained a buy rating with a price target of PLN 127.2.
News
Captor Therapeutics: PLN 36 m of cash at 30 September 2025, runway to mid-2026 - clinical data versus the cash clock
Wrocław-based Captor Therapeutics S.A. (KRS 0000756383) - a pre-commercial biotech specialising in TPD (Targeted Protein Degradation) - closed Q3 2025 with PLN 36 m of cash and grants securing financing to mid-2026. CT-01 (hepatocellular carcinoma) entered Phase I - the first patient dosed at Barcelona Clinic Liver Cancer. CT-03 (MCL-1 degrader) nearing clinical entry. Without a new R&D partnership or equity issuance in 2026, the company will need additional financing.
